Video presentations

Videos from Pharma Equity Group

To give you a glimpse into the work that we do at Pharma Equity Group A/S, we have created a series of video presentations, interviews, and other multimedia content that showcases and explains what Pharma Equity Group is and how we are developing. 

Our video presentations include in-depth explanations of company structure, share development, status of our pipelines and their market potential. 

Below is a video presentation featuring Reponex Pharmaceuticals’ Chief Medical Officer, Dr. Christopher Burton. Join us as Dr. Burton, a
trained medical professional with years of experience in the pharmaceutical industry, provides unique insights into what he brings to the Reponex team. 

In collaboration with HC Andersen Capital, Dr. Burton will guide you through the promising pipeline of Reponex Pharmaceuticals’
innovative drug candidates. This presentation promises to offer a glimpse into the future of the drug candidates and the potential that lies within Reponex Pharmaceuticals.

Listen to  CEO Thomas Kaas Selsø in a revealing podcast episode of “Aktier i fokus” with host Anders Egsvang, released on October 9, 2023. In this concise interview, you’ll uncover key insights:

Learn about Thomas Kaas Selsø’s background and his involvement with Reponex Pharmaceuticals.

Explore Reponex’s history, the decision to go public, and the unique corporate structure.

Understand Reponex’s focus on critical medical conditions and its innovative repositioning technology.

Gain insights into the company’s development stage, market impact, and financial strategy.

Discover future prospects and Thomas Kaas Selsø’s three essential watchlist items for investors.

Spotify: https://open.spotify.com/episode/04naZRNsTkgc3bKvCHP0vK?si=fe3220b34b2848d4
Apple Podcast: https://podcasts.apple.com/dk/podcast/aktier-i-fokus/id1657718967?l=da&i=1000630641780


In the video below we delve into the world of efficient stock markets and market parity. In this podcast, our CEO, Thomas Kaas Selsø, joins the studio alongside stock analyst Claus Thestrup from HC Andersen Capital. Together, they explore the challenges faced by smaller publicly traded companies seeking visibility in a market where media attention often gravitates towards corporate giants. They also discuss alternative strategies for entering the stock market, such as acquiring an already listed company and merging operational activities. Join us as we navigate the intricacies of financial markets and share insights that could reshape your perspective on investment opportunities.

You can also listen to it as podcast on: https://open.spotify.com/episode/1i99iZIC9sk1ttGmcIG4zn?si=8804d9ba9ea14974&nd=1

Pharma Equity Group’s CEO, Thomas Kaas Selsø, was invited to an episode of the acknowledged danish investment podcast “Millionærklubben”. Thomas presented the issues of the being a small company on the stock exchange in Denmark. This is what Millionærklubben wrote as an introduction to Thomas’ meeting: 

How do you find the next Novo Nordisk in the undergrowth of small companies if the media, analysts, and portfolio managers are not directing their focus in that direction?

It seems that everyone prefers to talk about and engage with the large C25 companies, which creates inefficient stock markets. At least, that’s the view of today’s guest, Thomas Kaas Selsø, CEO of the small-cap company Pharma Equity Group.”

 Watch the full episode below or listen to it as a podcast on Millionærklubbens own webpage under the episode name ” Kampen om opmærksomhed”  

In an interview, Pharma Equity Group (Reponex Pharmaceuticals), in collaboration with Dansk Aktionærforening, provided a platform for its CEO, Thomas Kaas Selsø, to discuss Reponex Pharmaceuticals’ ongoing battle against inflammatory diseases, particularly those affecting the bowel, intestines, and wound care. Thomas passionately emphasized the critical significance of shedding light on the severe inflammatory diseases that have a profound impact on patients’ lives. He eloquently detailed Reponex’s unwavering commitment to improving the treatment landscape for these debilitating conditions. It was a conversation that not only highlighted the urgency of our mission but also underscored the dedication of Reponex Pharmaceuticals in advancing medical solutions that hold the potential to transform and restore the lives of those affected by these life-altering diseases.

 Watch the full presentation and discussion in the video below.

During the 2023 Life Science Seminar 31 of August 2023, Reponex Pharmaceutical’s Chief Medical Officer, Dr. Christopher Burton, and CEO, Thomas Kaas Selsø, in partnership with HC Andersen Capital, delivered an insightful presentation. They shed light on their promising drug candidates aimed at addressing critical medical challenges. The audience gained valuable insights into potential treatments for conditions such as Bacterial Peritonitis, Pouchitis, Wound Healing, Crohn’s Disease, Colon Adenoma, and Colorectal Cancer. This collaborative effort showcased their commitment to advancing healthcare solutions and left attendees eager to see how these candidates might shape the future of medicine.

 Watch the full presentation and discussion in the video below.

On the 16th of August 2023, CEO Thomas Kaas Selsø presented the consolidated interim report for the first 6 months of 2023. The Presentation was done in collaboration with HC Andersen Capital. Watch the full presentation and discussion in the video below.

Below you can watch a presentation from CEO of Pharma Equity Group, Thomas Kaas Selsø. Thomas presents the interim financial report from first quarter of 2023. The interview is conducted in collaboration with HC Andersen Capital (In Danish). 

Below you can watch some of the highlights from Pharma Equity Groups’s first day on Nasdaq Copenhagen. The Team behind Pharma Equity Group visitied the Copenhagen stock exchange (In Danish). 

Watch the latest presentation from Pharma Equity Group with Forthcoming CEO Thomas Kaas Selsø. The presentation was done in collaboration with HC Andersen Capital. In the presentation Thomas elaborates on Pharma Equity Group’s market potential and how the first day on the stock exchange has been. (The presentation is in Danish).

Watch the presentation from Pharma Equity group with Forthcoming CEO Thomas Kaas Selsø and COO of Reponex pharmaceuticals A/S Torsten Bjørn. The presentation was done in collaboration with HC Andersen Capital. In the presentation Thomas and Torsten Elaborate on the clinical programs in Reponex Pharmaceuticals and the structure of Pharma Equity Group (The presentation is in danish).

Connect with us

Pharma Equity Group
Slotsmarken 18, 2.th.
DK-2970 Hørsholm
Denmark

Contact us at info@pharmaequitygroup.com